Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Roberto Alva‐Ruiz

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9796-8098; OpenAlex author ID A5019419286. Sources: OpenAlex.

Their work

Papers
9 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
36
Papers, trials and grants by year

2021: 1 paper · 2022: 3 papers · 2023: 3 papers · 2024: none · 2025: 2 papers

Papers 9

  1. Outcomes of Visceral Arterial Interposition Graft Reconstruction for Locally Advanced Pancreatic Cancer. First author DOI 10.1097/sla.0000000000006350↗
  2. Molecular KRAS ctDNA Predicts Metastases and Survival in Pancreatic Cancer: A Prospective Cohort Study. First author DOI 10.1245/s10434-025-17036-y↗
  3. Yield of Staging Laparoscopy for Pancreatic Cancer in the Modern Era: Analysis of More than 1,000 Consecutive Patients. Co-author DOI 10.1097/xcs.0000000000000704↗
  4. Interactive enhancer hubs (iHUBs) mediate transcriptional reprogramming and adaptive resistance in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2022-328154↗
  5. Identification of a ΔNp63-Dependent Basal-Like A Subtype-Specific Transcribed Enhancer Program (B-STEP) in Aggressive Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1541-7786.mcr-22-0916↗
  6. Patency rates of hepatic arterial resection and revascularization in locally advanced pancreatic cancer. Co-author DOI 10.1016/j.hpb.2022.06.005↗
  7. Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-10991-2↗
  8. FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.6004/jnccn.2022.7041↗
  9. Molecular Peritoneal Staging for Pancreatic Ductal Adenocarcinoma Using Mutant KRAS Droplet-Digital Polymerase Chain Reaction: Results of a Prospective Clinica… First author DOI 10.1016/j.jamcollsurg.2021.05.009↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jennifer A. Yonkus · 9 shared papers, 2021–2025 · strength 1.37
  2. Mark Joseph Truty · 9 shared papers, 2021–2025 · strength 1.37
  3. Michael L. Kendrick · 7 shared papers, 2021–2025 · strength 1.10
  4. Amro M. Abdelrahman · 7 shared papers, 2021–2025 · strength 0.96
  5. Sean Patrick Cleary · 6 shared papers, 2021–2025 · strength 0.86
  6. Travis Edward Grotz · 5 shared papers, 2021–2025 · strength 0.73
  7. Rondell Patrell Graham · 4 shared papers, 2022–2023 · strength 0.51
  8. Susanne Gray Warner · 3 shared papers, 2022–2025 · strength 0.48
  9. Cornelius A. Thiels · 3 shared papers, 2022–2025 · strength 0.48
  10. Robert R. McWilliams · 3 shared papers, 2022–2025 · strength 0.44
  11. Jennifer L. Leiting · 3 shared papers, 2021–2025 · strength 0.44
  12. Bernardo C. Mendes · 2 shared papers, 2022–2025 · strength 0.38
  13. Xin Wang · 2 shared papers, 2023 · strength 0.27
  14. Jochen Gaedcke · 2 shared papers, 2023 · strength 0.27
  15. Ana P. Kutschat · 2 shared papers, 2023 · strength 0.27
  16. Joana E. Aggrey-Fynn · 2 shared papers, 2023 · strength 0.27
  17. Stephan A. Hahn · 2 shared papers, 2023 · strength 0.27
  18. Steven A. Johnsen · 2 shared papers, 2023 · strength 0.27
  19. Feda H. Hamdan · 2 shared papers, 2023 · strength 0.27
  20. Zeynab Najafova · 2 shared papers, 2023 · strength 0.27
  21. Jens Thomas Siveke · 2 shared papers, 2023 · strength 0.27
  22. Elisabeth Heßmann · 2 shared papers, 2023 · strength 0.27
  23. Thorvardur Ragnar Halfdanarson · 2 shared papers, 2022 · strength 0.24
  24. Christopher Leigh Hallemeier · 2 shared papers, 2022 · strength 0.24
  25. Wen Wee Ma · 2 shared papers, 2022 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.